Table 4.

Change in Creatine Kinase–Myocardial Band at 16 and 24 Hours After PCI in Patients With Short and Long Time Intervals Between Study Drug Infusion and PCI

	Short (Less Than Median) Time Interval			Long (Greater Than Median) Time Interval
	Placebo	Inclacumab (5 mg/kg)	Inclacumab (20 mg/kg)	Placebo	Inclacumab (5 mg/kg)	Inclacumab (20 mg/kg)
Baseline GM (IQR)	10.76 (3.95–30.00)	7.41 (2.40, 21.65)	7.99 (2.75–17.85)	8.37 (3.20–21.30)	7.68 (3.30–12.90)	7.71 (3.30–14.50)
16 hours after PCI GM	10.96 (n=56)	8.36 (n=48)	7.10 (n=54)	8.40 (n=58)	7.50 (n=46)	7.33 (n=53)
Adjusted GM percent change from baseline to 16 hours	31.0	24.6	−3.0	12.8	5.8	1.8
Placebo‐adjusted GM percent change at 16 hours		−4.9	−26.0		−6.2	−9.8
95% CI		−30.0 to 29.2	−45.1 to −0.2		−30.9 to 27.3	−33.0 to 21.3
P value		0.75	0.049		0.68	0.49
24 hours after PCI GM	8.99 (n=50)	6.96 (n=45)	5.56 (n=52)	7.30 (n=54)	6.22 (n=47)	6.02 (n=49)
Adjusted GM percent change from baseline to 24 hours	26.6	16.5	−12.3	12.2	1.4	−5.4
Placebo‐adjusted GM percent change at 24 hours		−8.0	−30.7		−9.6	−15.7
95% CI		−32.1 to 24.7	−48.4 to −7.0		−32.6 to 21.2	−37.0 to 12.9
P value		0.59	0.01		0.50	0.25

GM indicates geometric mean; IQR, interquartile range; PCI, percutaneous coronary intervention.